Skip to content

Robert Tanguay

4 papers in the library · 65 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program

Journal of Military Veteran and Family Health February 1, 2026 Ian Stefanuk, Kaitlin Chivers-Wilson, Rakesh Jetly et al.

Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans, and the presence of multiple conditions requires innovative treatment approaches. The Newly Institute in Calgary, Alberta, Canada, has introduced a novel intervention combining sublingual ketamine therapy with a medically managed transdiagnostic...

Role of ketamine in the treatment of substance use disorders: A systematic review.

Journal of Substance Use and Addiction Treatment August 1, 2025 Reinhard Janssen-Aguilar, Shakila Meshkat, Ilya Demchenko et al. 12 citations

Substance Use Disorders (SUDs) involve diminished control, risky use, impaired social interactions, and physical dependence. Despite their global prevalence and burden, treatment options remain limited. Ketamine (KET), an NMDA receptor antagonist, may aid SUD treatment by modulating glutamatergic neurotransmission. This systematic review evaluates KET's role in SUD treatment. This review...

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.

Neuroscience and Biobehavioral Reviews June 1, 2025 Shakila Meshkat, Gunjan Malik, Richard J. Zeifman et al. 11 citations

Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remain uncertain. This systematic review assessed the safety and efficacy of psilocybin for SUDs through a systematic database search conducted via OVID on May 22, 2024, and summarized 26 ongoing clinical trials registered on clinicaltrials.gov. Among 16...

Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing

CNS Drugs February 14, 2022 Jennifer Swainson, L. Klassen, Stefan Brennan et al. 42 citations

Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression. The clinical utility of these treatments is limited by a paucity of publicly funded IV ketamine and IN esketamine programs and cost barriers to private treatment programs, as...